Literature DB >> 18413480

Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication.

Anne M Remes1, Lauri Laru, Hannu Tuominen, Sargo Aalto, Nina Kemppainen, Helinä Mononen, Kjell Någren, Riitta Parkkola, Juha O Rinne.   

Abstract

OBJECTIVE: To investigate amyloid accumulation by carbon 11-labeled Pittsburgh Compound B (11C-PiB) in hereditary cerebral amyloid angiopathy and APP locus duplication. DESIGN, SETTING, AND PATIENTS: Positron emission tomography with 11C-PiB and magnetic resonance imaging were performed for 2 patients, 49-year-old and 60-year-old siblings with APP locus duplication, with hereditary Alzheimer disease and cerebral amyloid angiopathy. MAIN OUTCOME MEASURE: Change in 11C-PiB uptake.
RESULTS: Uptake of 11C-PiB was increased especially in the striatum (caudate nucleus to 225% and 280% of the control mean and putamen to 166% and 185% of the control mean) and in the posterior cingulate (to 168% and 198% of the control mean), and it was marginally increased in other cortical brain areas. The pattern of increased 11C-PiB uptake was different from that seen in sporadic Alzheimer disease.
CONCLUSIONS: Amyloid imaging with 11C-PiB positron emission tomography is a useful tool for detecting in vivo amyloid accumulation in patients with hereditary cerebral amyloid angiopathy. However, the pattern of 11C-PiB accumulation differs between patients with typical AD and patients with APP locus duplication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413480     DOI: 10.1001/archneur.65.4.540

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  34 in total

1.  Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's.

Authors:  Lisa Mosconi; Juha O Rinne; Wai H Tsui; Valentina Berti; Yi Li; Huiyu Wang; John Murray; Noora Scheinin; Kjell Någren; Schantel Williams; Lidia Glodzik; Susan De Santi; Shankar Vallabhajosula; Mony J de Leon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

Review 2.  Clinical applications of PET amyloid imaging: an update.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-07       Impact factor: 9.236

3.  Whatever happened to Pittsburgh Compound-A?

Authors:  William E Klunk; Chester A Mathis
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

Review 4.  Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.

Authors:  Lisa Mosconi; Valentina Berti; Lidia Glodzik; Alberto Pupi; Susan De Santi; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 5.  Alzheimer mechanisms and therapeutic strategies.

Authors:  Yadong Huang; Lennart Mucke
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

6.  Frontal cortex and striatal cellular and molecular pathobiology in individuals with Down syndrome with and without dementia.

Authors:  Sylvia E Perez; Jennifer C Miguel; Bin He; Michael Malek-Ahmadi; Eric E Abrahamson; Milos D Ikonomovic; Ira Lott; Eric Doran; Melissa J Alldred; Stephen D Ginsberg; Elliott J Mufson
Journal:  Acta Neuropathol       Date:  2019-02-07       Impact factor: 17.088

Review 7.  Development of positron emission tomography β-amyloid plaque imaging agents.

Authors:  Chester A Mathis; N Scott Mason; Brian J Lopresti; William E Klunk
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

Review 8.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 9.  The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation.

Authors:  William E Klunk; Chester A Mathis
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

Review 10.  Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo.

Authors:  G D Rabinovici; W J Jagust
Journal:  Behav Neurol       Date:  2009       Impact factor: 3.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.